Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update: In collaboration with the World Health Organization, GA(2)LEN and AllerGen;ARIA update 2008: Die allergische rhinitis und ihr einfluss auf das asthma

Allergologie

Volumn 32, Issue 8, 2009, Pages 306-319

  Bousquet, J ^b   Khaltaev, N ^b   Cruz, A A ^b   Denburg, J ^b   Fokkens, W ^b   Togias, A ^b   Zuberbier, T ^b   Baena Cagnani, C ^b   Canonica, G W ^b   Van Weel, C ^b   Agache, I ^b   Ait Khaled N ^b   Bachert, C ^a   Blaiss, M ^b   Bonini, S ^b   Boulet, L P ^b   Bousquet, P J ^b   Camargos, P ^b   Carlsen, K H ^b   Custovic, A ^b   Chen, Y ^b   Dahl, R ^b   Demoly, P ^b   Douagui, H ^b   Durham, S ^b   Van Wijk, R G ^b   Kalayci, O ^b   Kaliner, M ^b   Kim, Y Y ^b   Kowalski, M L ^b   Kuna, P ^b   Lemiere, C ^b   Tuyet Lan, L T ^b   Li, J ^b   Lockey, R ^b   Mavale, S ^b   Meltzer, E O ^b   Mohammad, Y ^b   Mullol, J ^b   Naclerio, R ^b   OHehir, R ^b   Ohta, K ^b   Ouedraogo, S ^b   Palkonen, S ^b   Papadopoulos, N ^b   Passalacqua, G ^b   Pawankar, R ^b   Popov, T ^b   Rabe, K ^b   Rosado Pinto, J ^b   Scadding, G ^b   Simons, F E R ^b   Toskala, E ^b   Valovirta, E ^b   Van Cauwenberge, P ^b   Wang, D Y ^b   Wickman, M ^b   Yawn, B ^b   Yorgancioglu, A ^b   Yusuf, O ^b   Zar, H ^b   more..

^a GHENT UNIVERSITY   (Belgium)

^b NONE

Author keywords

Allergic rhinitis; Asthma; Diagnosis; Guidelines; Therapy

Indexed keywords

ALLERGIC RHINITIS; ASTHMA; REVIEW;

EID: 70349123402     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp32306     Document Type: Review

References (170)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108: 147-334.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999; 318: 593-596.
3. Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005; 60: 1112-1115. (Pubitemid 41153135)
4. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B et al. ARIAupdate: I - Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006; 117: 1054-1062.
5. Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006; 61: 1086-1096. (Pubitemid 44175216)
6. Bonini S, Bonini M, Bousquet J, Brusasco V, Canonica GW, Carlsen KH et al. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN.Allergy. 2006; 61: 681-692.
7. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007; 119: 881-891. (Pubitemid 46527840)
8. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004; 24: 758-764. (Pubitemid 39504428)
9. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005; 60: 350-353. (Pubitemid 40293352)
10. Leger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, Pribil C et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med. 2006; 166: 1744-1748. (Pubitemid 44414463)
11. Stuck BA, Czajkowski J, Hagner AE, Klimek L, Verse T, Hormann K et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004; 113: 663-668. (Pubitemid 38530420)
12. Santos CB, Pratt EL, Hanks C, McCann J, Craig TJ. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol. 2006; 97: 579-586, quiz 86-89, 671. (Pubitemid 44851452)
13. Craig TJ, Mende C, Hughes K, Kakumanu S, Lehman EB, Chinchilli V. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc. 2003; 24: 53-58. (Pubitemid 37034208)
14. Zwillich CW, Pickett C, Hanson FN, Weil JV. Disturbed sleep and prolonged apnea during nasal obstruction in normal men. Am Rev Respir Dis. 1981; 124: 158-160. (Pubitemid 11044492)
15. Olsen KD, Kern EB, Westbrook PR. Sleep and breathing disturbance secondary to nasal obstruction. Otolaryngol Head Neck Surg. 1981; 89: 804-810. (Pubitemid 12241680)
16. McNicholas WT, Tarlo S, Cole P, Zamel N, Rutherford R, Griffin D et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis.Am Rev Respir Dis. 1982; 126: 625-628.
17. Houston D, Williams AJ, Finberg S, Santiago S, Wald R. Disturbed sleep and prolonged apnea during nasal obstruction in normal men. Am Rev Respir Dis. 1982; 125: 484-485.
18. Lavie P, Gertner R, Zomer J, Podoshin L. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol. 1981; 92: 529-533.
19. Sundberg R, Toren K, Hoglund D, Aberg N, Brisman J. Nasal symptoms are associated with school performance in adolescents. J Adolesc Health. 2007; 40: 581-583. (Pubitemid 46783884)
20. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007; 120: 381-387.
21. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol. 1998; 101: 633-637. (Pubitemid 28228307)
22. Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin. 2004; 20: 1937-1952.
23. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc. 1996; 17: 185-189.
24. Vuurman EF, van-Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on childrens learning. Ann Allergy. 1993; 71: 121-126.
25. Vuurman EF, van-Veggel LM, Sanders RL, Muntjewerff ND, O'Hanlon JF. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996; 76: 247-252.
26. Kessler RC, Almeida DM, Berglund P, Stang P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol. 2001; 87: 289-295. (Pubitemid 32973297)
27. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005; 4: 439-446. (Pubitemid 41803329)
28. Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998; 81: 463-468. (Pubitemid 28553777)
29. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006; 117: 158-162. (Pubitemid 43017154)
30. Demoly P, Allaert FA, Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002; 57: 546-554. (Pubitemid 34539130)
31. Blanc PD, Trupin L, Eisner M, EarnestG, Katz PP, Israel Let al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemiol. 2001; 54: 610-618. (Pubitemid 32453355)
32. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005; 60: 788-794. (Pubitemid 40769882)
33. Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol. 2005; 136: 148-154. (Pubitemid 40463239)
34. Smith TA, Patton J. Health surveillance in milling, baking and other food manufacturing operations - five years experience. Occup Med. 1999; 49: 147-153. (Pubitemid 29231919)
35. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J. 2003; 21: 116-122. (Pubitemid 36150311)
36. Malm L, Gerth van Wijk R, Bachert C. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. Rhinology. 2000; 38: 1-6.
37. Riechelmann H, Bachert C, Goldschmidt O, Hauswald B, Klimek L, SchlenterWWet al. Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology. Laryngorhinootologie. 2003; 82: 183-188.
38. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490.
39. Global Strategy for Asthma Management and Prevention. GINA. Update from NHLBI/WHO Workshop Report 1995. Revised 2006. www.ginasthma.com 2006.
40. Sheikh A, Hurwitz B, Shehata Y. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2007; CD001563.
41. Gotzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. Cochrane Database Syst Rev. 2004; CD001187.
42. Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med. 2003; 349: 237-246. (Pubitemid 36859475)
43. Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z, Oosting AJ, de Monchy JG, Bruijnzeel-Koomen CA et al. The effect of encasings on quality of life in adult house dust mite allergic patients with rhinitis, asthma and/or atopic dermatitis. Allergy. 2005; 60: 888-893. (Pubitemid 40813810)
44. Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol. 2003; 91: 189-194. (Pubitemid 36999480)
45. Cullinan P, Tarlo S, Nemery B. The prevention of occupational asthma. Eur Respir J. 2003; 22: 853-860.
46. Vandenplas O, Jamart J, Delwiche JP, Evrard G, Larbanois A. Occupational asthma caused by natural rubber latex: outcome according to cessation or reduction of exposure. J Allergy Clin Immunol. 2002; 109: 125-130. (Pubitemid 34112142)
47. Management of allergic and nonallergic rhinitis. Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 67. AHRQ Publication No 02-E024; 2002.
48. Management of allergic rhinitis in the working-age population. Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 67.AHRQPublication No 03-E015; 2003.
49. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 (Suppl 86): 8-160. (Pubitemid 351357811)
50. Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol. 1996; 98: 309-316. (Pubitemid 126749679)
51. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004; 114: 838-844. (Pubitemid 39330255)
52. Guadano EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004; 59: 766-771. (Pubitemid 38850353)
53. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998; 317: 1624-1629.
54. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002; 89: 479-484. (Pubitemid 36187991)
55. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002; 23: 407-413.
56. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105: E22.
57. Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther. 2004; 26: 1905-1919.
58. Fink RS, Pierre LN, Daley-Yates PT, Richards DH, Gibson A, Honour JW. Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab. 2002; 87: 4541-4546. (Pubitemid 35247038)
59. The current status of allergen immunotherapy (hyposensitisation). Report of aWHO/IUIS working group. Allergy. 1989; 44: 369-379.
60. Bousquet J, Lockey R, Malling H. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998; 53 (Suppl 54): 1-42. (Pubitemid 28346358)
61. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006; 61 (Suppl 82): 1-20. (Pubitemid 44366956)
62. Malling H. Immunotherapy. Position Paper of the EAACI. Allergy. 1987; 42: 401-413.
63. Malling H,Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy. 1993; 48: 9-35.
64. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B, Bousquet J, Caillot D et al. Local immunotherapy. Allergy. 1998; 53: 933-944.
65. International Asthma Management Project. International Consensus Report on Diagnosis and Management of Asthma. Allergy. 1992; 47: 1-61.
66. National Institutes of Health, National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention. WHO/NHLBI Workshop Report; Publication Number 95-3659, 1995.
67. International Rhinitis Management Working Group. International Consensus Report on Diagnosis and Management of Rhinitis. Allergy. 1994; 49: 1-34.
68. Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical ImmunologyWorking Party. BMJ. 1993; 307: 919-923.
69. Nicklas R, Bernstein I, Blessing-Moore J, Fireman S, Gutman A, Lee R et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol. 1996; 6: 1001-1011.
70. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of aWorld Allergy Organization (WAO) taskforce. Allergy. 2007; 62: 317-324.
71. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999; 54: 1022-1041. (Pubitemid 29482002)
72. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003; CD001186.
73. Calderon M, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007; CD001936.
74. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol. 2001; 87: 38-42.
75. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 1996; 51: 430-433.
76. Durham SR,Walker SM, Varga EM, Jacobson MR, OBrien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341: 468-475. (Pubitemid 29372886)
77. Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol. 2007; 98: 416-426.
78. Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf. 1994; 10: 5-17. (Pubitemid 24032936)
79. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987; 79: 660-677.
80. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117: 319-325. (Pubitemid 43190146)
81. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005; 60: 801-807. (Pubitemid 40769884)
82. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005; 116: 608-613. (Pubitemid 41267135)
83. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000; 17: 37-52.
84. Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol. 2007; 39: 148-156. (Pubitemid 46954542)
85. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol. 1984; 73: 484-489.
86. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy. 1988; 43: 523-529. (Pubitemid 18253363)
87. Naclerio RM, Proud D, Moylan B, Balcer S, Freidhoff L, Kagey-Sobotka A et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997; 100: 293-300. (Pubitemid 27402769)
88. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001; 31: 1392-1397.
89. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006; 61: 198-201. (Pubitemid 43381830)
90. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007; 17: 85-91. (Pubitemid 46623709)
91. Des-Roches A, Paradis L, Ménardo J-L, Bouges S, Daurès J-P, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997; 99: 450-453. (Pubitemid 27173080)
92. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109: 251-256. (Pubitemid 34158289)
93. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A et al. Five-year follow-up on the PAT study: specific immunotherapy and longterm prevention of asthma in children. Allergy. 2006; 61: 855-859. (Pubitemid 43893987)
94. Passalacqua G, Lombardi C, Canonica GW. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol. 2004; 4: 31-36.
95. Didier A. Future developments in sublingual immunotherapy. Allergy. 2006; 61 (Suppl 81): 29-31. (Pubitemid 43823250)
96. Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy. 2006; 61 (Suppl 81): 20-23. (Pubitemid 43823248)
97. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005; 60: 4-12.
98. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117: 802-809.
99. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004; 59: 1205-1210. (Pubitemid 39389476)
100. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol. 2005; 115: 1184-1188. (Pubitemid 40824587)
101. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004; 59: 491-497. (Pubitemid 38580768)
102. Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004; 59: 498-504. (Pubitemid 38580769)
103. Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child. 2004; 89: 620-624. (Pubitemid 38868519)
104. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. 2003; 33: 1641-1647. (Pubitemid 38005382)
105. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol. 2004; 114: 831-837. (Pubitemid 39330254)
106. Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV et al. A prospective, randomized, double-blind, placebo-controlled multicentre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy. 2004; 59: 1285-1293. (Pubitemid 39506727)
107. Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004; 93: 425-430. (Pubitemid 39507708)
108. Dahl R, Stender A, Rak S. Specific immunotherapy with SQstandardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006; 61: 185-190. (Pubitemid 43381828)
109. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006; 61: 849-854. (Pubitemid 43893986)
110. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007; 62: 954-957. (Pubitemid 47037852)
111. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 118: 434-440. (Pubitemid 44160721)
112. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008; 121: 512-518.
113. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 120: 1338-1345. (Pubitemid 350225683)
114. Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A,Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009; 64: 166-171.
115. Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res. 2007; 16: 191-201. (Pubitemid 46088353)
116. Roder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol. 2007; 119: 892-898. (Pubitemid 46527818)
117. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust miteinduced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007; 18: 47-57. (Pubitemid 46232283)
118. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005; 15: 9-16.
119. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009; 123: 167-173.
120. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009; 123: 160-166.
121. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003; 111: 437-448, quiz 49.
122. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006; 61: 181-184. (Pubitemid 43381827)
123. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000; 121: 229-234. (Pubitemid 30157710)
124. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003; 5: 777-781. (Pubitemid 37452626)
125. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005; 60: 133.
126. Pham-Thi N, de Blic J, Scheinmann P. Sublingual immunotherapy in the treatment of children. Allergy. 2006; 61 (Suppl 81): 7-10. (Pubitemid 43823245)
127. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy. 1999; 54: 1110-1113. (Pubitemid 29482012)
128. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy. 2006; 61: 1235.
129. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006; 61: 1236-1237.
130. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005; 115: 459-465. (Pubitemid 40341694)
131. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001; 286: 2956-2967. (Pubitemid 33140359)
132. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, ZetterstromOet al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 106: 253-259. (Pubitemid 30644998)
133. Kaliner MA. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004; 4: 237-244.
134. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 91: 160-167. (Pubitemid 36999475)
135. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59: 709-717. (Pubitemid 38850345)
136. Price K, Hamilton R. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007; 28: 313-319.
137. Information for health care professionals. Omalizumab (marketed as Xolair). July 2, 2007. http: //www.fda.gov/Cder/drug/InfoSheets/HCP/ omalizumabHCP.htm. 2007.
138. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol.2006; 117: 134-140.
139. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109: 274-280. (Pubitemid 34158294)
140. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59: 973-979. (Pubitemid 39141410)
141. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007; 120: 688-695. (Pubitemid 47320761)
142. Mori S, Fujieda S, Igarashi M, Fan GK, Saito H. Submucous turbinectomy decreases not only nasal stiffness but also sneezing and rhinorrhea in patients with perennial allergic rhinitis (In Process Citation). Clin Exp Allergy. 1999; 29: 1542-1548. (Pubitemid 29519286)
143. Ellegard EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol. 2004; 26: 149-159.
144. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs. 2003; 63: 1813-1820.
145. Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J Am Board Fam Med. 2007; 20: 289-298. (Pubitemid 46871219)
146. Taramarcaz P, Gibson P. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev. 2003; 4: CD003570.
147. Dahl R, Nielsen LP, Kips J, Foresi A, Cauwenberge P, Tudoric N et al. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy. 2005; 60: 875-881. (Pubitemid 40813808)
148. Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J. 1998; 11: 1268-1273. (Pubitemid 28298587)
149. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004; 20: 1549-1558. (Pubitemid 39457543)
150. Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CMet al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol. 2006; 96: 60-68.
151. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy. 2005; 35: 723-727. (Pubitemid 40961343)
152. Global Strategy for Asthma Management and Prevention. GINA. Update fromNHLBI/WHOWorkshop Report 1995, Revised 2002. NIH Publication Number 02-3659; 2002.
153. Walker SM, Pajno GB, Lima MT,Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001; 107: 87-93. (Pubitemid 32105250)
154. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006; 117: 263-268. (Pubitemid 43190138)
155. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978; 2: 912-915.
156. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988; 82: 439-446. (Pubitemid 18238312)
157. Bousquet J, Maasch HJ, Hejjaoui A, Skassa-Brociek W, Wahl R, Dhivert H et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 1989; 84: 546-556. (Pubitemid 19266752)
158. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol. 1990; 85: 490-497. (Pubitemid 20075187)
159. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996; 334: 501-506.
160. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy. 1998; 53: 493-498. (Pubitemid 28248417)
161. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, Kagey-Sobotka A, Khattignavong A, Norman PS Jr et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988; 82: 1055-1068.
162. Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol. 1992; 89: 925-933.
163. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000; 30: 1423-1429.
164. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy. 2006; 36: 254-260. (Pubitemid 43344706)
165. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006; 61: 843-848. (Pubitemid 43893985)
166. Johnstone DE. Immunotherapy in children: past, present, and future. (Part I). Ann Allergy. 1981; 46: 1-7. (Pubitemid 11176842)
167. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003; 33: 206-210. (Pubitemid 36241378)
168. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002; 109: 57-62. (Pubitemid 34112130)
169. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002; 109: 636-642. (Pubitemid 34327190)
170. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004; 113: 415-419. (Pubitemid 38338943)